蒲地蓝消炎口服液联合重组人干扰素治疗儿童手足口病临床研究

Clinical Study on Pudilan Antiphlogistic Oral Liquid Combined with Recombinant Interferon for Children with Hand-Foot-Mouth Disease

目的:观察蒲地蓝消炎口服液联合重组人干扰素治疗儿童手足口病(HFMD)的临床疗效及对患儿血清肌酸激酶同工酶(CK-MB)、肌钙蛋白I(cTnI)的影响。方法:回顾性分析64例HFMD患儿的临床资料,根据资料中的治疗方法将患儿分为对照组及治疗组各32例。对照组接受重组人干扰素α2b注射液治疗,治疗组在对照组基础上加用蒲地蓝消炎口服液治疗。比较2组治疗前后血清CK-MB、cTnI及炎性因子水平,比较2组治疗后临床疗效及临床症状改善时间,并比较2组不良反应。结果:治疗组总有效率93.75%,高于对照组75.00%(P<0.05)。与对照组比较,治疗组退热时间、溃疡消退时间、口腔黏膜充血消退时间与皮疹消退时间均较短(P<0.05)。与同组治疗前比较,2组治疗后血清CK-MB、cTnI、肿瘤坏死因子-α(TNF-α)、超敏C-反应蛋白(hs-CRP)水平均降低(P<0.05),干扰素-γ(IFN-γ)水平升高(P<0.05);与对照组治疗后比较,治疗组治疗后血清CK-MB、cTnI、TNF-α、hs-CRP水平均较低(P<0.05),IFN-γ水平较高(P<0.05)。2组不良反应比较,差异无统计学意义(P>0.05)。结论:应用蒲地蓝消炎口服液联合重组人干扰素治疗HFMD患儿能取得较好的临床疗效,及时缓解患儿的临床症状,降低血清CK-MB、cTnI及炎性因子水平,且不良反应少。

Objective:To observe the clinical effect of Pudilan antiphlogistic oral liquid combined with recombinant interferon for children with hand-foot-mouth disease(HFMD)and its effects on creatine kinase MB(CK-MB)and cardiac troponin I(cTnI)in serum in children.Methods:The clinical data of 64 cases of HFMD children were retrospectively analyzed,and the children were divided into the control group and the treatment group according to the treatment methods in data,with 32 cases in each group.The control group was treated with recombinant human interferonα2b injection,and the treatment group was additionally treated with Pudilan antiphlogistic oral liquid based on the treatment of the control group.The levels of CK-MB,cTnI and inflammatory factors in serum before and after treatment in the two groups were compared;the clinical effects and improvement time of clinical symptoms after treatment in the two groups were compared;the adverse reactions in the two groups were compared.Results:The total effective rate was 93.75%in the treatment group,higher than that of 75.00%in the control group(P<0.05).The antipyretic time,the subsided time of ulcer,oral mucosal congestion and the rash in the treatment group were shorter than those in the control group(P<0.05).After treatment,the levels of CKMB,cTnI,tumor necrosis factor-α(TNF-α)and high-sensitivity C-reactive protein(hs-CRP)in serum in the two groups were decreased when compared with those before treatment(P<0.05),and the levels of interferon-γ(IFN-γ)in serum were increased(P<0.05).After treatment,the levels of CK-MB,cTnI,TNF-αand hs-CRP in serum in the treatment group were lower than those in the control group(P<0.05),and the level of IFN-γin serum was higher(P<0.05).There was no significant difference being found in the comparison of the incidences of adverse reactions between the two groups(P>0.05).Conclusion:The application of Pudilan antiphlogistic oral liquid combined with recombinant interferon for HFMD children can achieve a good clinical effect,which can timely relieve their clinical symptoms,reduce the levels of CK-MB,cTnI and inflammatory factors in serum,with fewer adverse reactions.